Regeneron Pharmaceuticals is a biotechnology company founded in 1988 that discovers, develops and commercializes medicines for serious diseases. The company employs more than 15,000 people, including over 1,400 with MDs and PhDs, and was founded and continues to be led by physician-scientists. Nearly all of its approved treatments and product candidates have been developed internally within its own laboratories.
The company's core technological capabilities centre on antibody discovery and engineering. VelociSuite® is its proprietary platform for discovering optimized fully human antibodies and bispecific antibodies. The Regeneron Genetics Center® applies genetics-driven data analysis to inform drug discovery and development. The company has also developed platforms for genetic medicine as it works to pioneer the next frontier of treatment.
Regeneron operates across multiple therapeutic areas including ophthalmology, allergic and inflammatory conditions, oncology, cardiovascular diseases, metabolic diseases, neurological disorders, hematologic conditions, infectious diseases and rare diseases. The company maintains a global network and maintains a relentless focus on translating scientific discovery into clinical medicine.